Opko Health Inc Shares Close the Week 21.4% Higher - Weekly Wrap
The company saw its shares close the week 21.4% higher than last week, with trading volume higher than its 30 day average.
Jun 30, 2023 by Kwhen Finance Editors
Opko Health Inc (OPK) shares closed this week 21.4% higher than it did at the end of last week. The stock is currently up 56.4% year-to-date, down 24.5% over the past 12 months, and down 58.4% over the past five years. This week, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.4%.
Trading Activity
- Shares traded as high as $2.08 and as low as $1.56 this week.
- Trading volume this week was 47.7% higher than the 10-day average and 166.8% higher than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Fundamentals & Catalysts
- Over the past 12 months the company generated $186 million in earnings before interest and taxes from $1 billion in revenue. It currently holds $89 million in cash and $403 million in debt.
- Its forward price-to-earnings (P/E) ratio of 31.833334044863793 is higher than its current P/E ratio of -5.19, implying that analysts are expecting a decrease in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 0.15. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.49 which means it currently has $1.49 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 1.51. This means that the stock is trading at a premium of 2 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 1.45.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 1.54.
P/E
-5.19
EBITDA
$186M
P/Book
1.51
Mkt Cap
$1B
P/Sales
1.45
Revenue
$1B
EPS (TTM)
-0.39
PEG Ratio
0.15
EV/Revenue
1.54
Total Cash
$89M
Debt/Equity
1.49
Forward P/E
31.83
Current Debt
$403M
Gross Profit
$651M
Dividend Date
-
Earnings Date
2023-08-03
Profit Margin
0.07
Revenue/Share
2.64
Total Revenue
$1B
Enterprise Val
$2B
Put/Call Ratio
0.95
Revenue/Employee
290208.66
Market Comparative Performance
- The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Opko Health Inc | 1.1 | 56.4 | -24.5 | ||
| Dow Jones Industrial Average | 0.8 | 4.5 | 12.8 | -0.7 | 22.2 |
| S&P 500 Index | 1.2 | 15.9 | 17.5 | -0.5 | 28.8 |
| Health Care | 1.2 | -1.6 | 4.1 | -4.6 | 12.5 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date beats the peer average by -1383.6%
- The company's stock price performance over the past 12 months lags the peer average by -138.8%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Opko Health Inc | OPK | -5.2 | 56.4 | -24.5 | ||
| Peer Avg | N/A | 12.0 | -4.4 | 63.2 | -9.2 | 8.0 |
| Johnson & Johnson | JNJ | 33.5 | -5.7 | -4.7 | -7.6 | 10.7 |
| Abbott Laboratories | ABT | 32.3 | -1.0 | 0.5 | -5.8 | 16.9 |
| Bristol-Myers Squibb Co. | BMY | 18.4 | -9.6 | -15.7 | -19.8 | 2.2 |
| Regeneron Pharmaceuticals, Inc. | REGN | 18.6 | -1.8 | 18.5 | ||
| Alnylam Pharmaceuticals Inc | ALNY | -22.3 | -19.6 | 31.4 | ||
| Laboratory Corp. Of America Holdings | LH | 21.3 | 2.8 | 1.4 | -6.8 | 22.1 |
| Teva- Pharmaceutical Industries Ltd. - ADR | TEVA | -5.3 | -17.0 | -4.8 | -33.4 | 12.4 |
| Ardelyx Inc | ARDX | 0 | 16.8 | 479.1 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: